Success Metrics

Active Trials
5(100%)

Phase Distribution

Ph phase_3
4
80%
Ph phase_2
1
20%

Phase Distribution

0

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
4(80.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Recruiting3
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
5
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 21 (20.0%)
Phase 34 (80.0%)

Trials by Status

active_not_recruiting240%
recruiting360%

Recent Activity

5 active trials
Showing 5 of 5
recruitingphase_3

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

NCT04267848
recruitingphase_3

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

NCT06958328
active_not_recruitingphase_3

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

NCT03737981
active_not_recruitingphase_3

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

NCT02595944
recruitingphase_2

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

NCT05541016

Clinical Trials (5)

Showing 5 of 5 trials
NCT04267848Phase 3

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Recruiting
NCT06958328Phase 3

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Recruiting
NCT03737981Phase 3

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

Active Not Recruiting
NCT02595944Phase 3

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

Active Not Recruiting
NCT05541016Phase 2

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

Recruiting

All 5 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
5